Fundraising Fox
/Companies
Sign in

Neuralymed

Germantown, US · Founded 2016 · Delaware corporation · 1 known investors

Find your way into Neuralymed

Sign up to see every warm intro you have to Neuralymed

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Neuralymed team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Neuraly is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative disorders, focusing on inhibiting pathological glial activation to prevent neuronal cell death. Its lead candidate NLY01 has been evaluated in Phase 2 trials for early Parkinson's disease.

BiotechHealthtech

Founders & leadership

Neuralymed was founded in 2016 by Seulki Lee, Viktor Roschke, Ted Dawson, Martin Pomper, and Han Seok Ko.

SL
Seulki LeeCEO
VR
Viktor RoschkeCo-Founder, Advisor
TDTed Dawson
Ted DawsonScientific Co-Founder, Advisor
MPMartin Pomper
Martin PomperScientific Co-Founder, Advisor
HS
Han Seok KoScientific Co-Founder, Advisor

Investors · 1

Reported raises · per SEC filings

Form D private placements

$10.5M disclosed across 2 rounds · 2016–2018

▶$10.4MraisedApr 2018 · 25 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Seulki LeeExecutive Officer, Director
  • Viktor RoschkeExecutive Officer, Director
Offering amount
$10.4M
Amount sold
$10.4M
First sale
Apr 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedDec 2016 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Seulki LeeExecutive Officer
Offering amount
$1.5M
Amount sold
$100K
Minimum investment
$10K
First sale
Sep 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

Companies working in the same space as Neuralymed.

Frequently asked questions

What does Neuralymed do?
Neuraly is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative disorders, focusing on inhibiting pathological glial activation to prevent neuronal cell death. Its lead candidate NLY01 has been evaluated in Phase 2 trials for early Parkinson's disease.
Who founded Neuralymed?
Neuralymed was founded by Seulki Lee, Viktor Roschke, Ted Dawson, Martin Pomper, Han Seok Ko in 2016.
Who are Neuralymed's investors?
Neuralymed's investors include Octave Ventures Llc.
How much funding has Neuralymed raised?
Neuralymed has disclosed $10.5M raised across 2 rounds.
Where is Neuralymed headquartered?
Neuralymed is headquartered in Germantown, US.